Amyl nitrite clinical pharmacology: Difference between revisions
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
==Clinical pharmacology== | ==Clinical pharmacology== | ||
Amyl nitrite causes a non specific relaxation of smooth muscle with the most prominent actions occurring in vascular smooth muscle. This effect on vascular smooth muscle results in coronary vasodilation and decreased systemic vascular resistance and left ventricular preload and afterload. Myocardial ischemia is relieved in patients with angina pectoris, with an abatement of chest pain and possibly other related symptons. Amyl nitrite vapors are absorbed rapidly through the pulmonary alveoli, manifesting therapeutic effects within one minute after inhalation. The drug is metabolized rapidly, probably by hydrolytic denitration; approximately one-third of the inhaled amyl nitrite is excreted in the urine.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AMYL NITRITE INHALANT [JAMES ALEXANDER CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c1b6e536-df5f-4f76-8e3c-6dc2f1e9975e | publisher = | date = | accessdate = 30 January 2014 }}</ref> | Amyl nitrite causes a non specific relaxation of smooth muscle with the most prominent actions occurring in vascular smooth muscle. This effect on vascular smooth muscle results in coronary [[vasodilation]] and decreased systemic vascular resistance and left ventricular [[preload]] and [[afterload]]. [[Myocardial ischemia]] is relieved in patients with [[angina pectoris]], with an abatement of chest pain and possibly other related symptons. Amyl nitrite vapors are absorbed rapidly through the [[pulmonary alveoli]], manifesting therapeutic effects within one minute after inhalation. The drug is metabolized rapidly, probably by hydrolytic denitration; approximately one-third of the inhaled amyl nitrite is excreted in the urine.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AMYL NITRITE INHALANT [JAMES ALEXANDER CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c1b6e536-df5f-4f76-8e3c-6dc2f1e9975e | publisher = | date = | accessdate = 30 January 2014 }}</ref> | ||
Revision as of 23:45, 30 January 2014
| Amyl nitrite |
|---|
| Amyl nitrite tablet® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Overdosage |
| Description |
| Clinical Pharmacology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
Clinical pharmacology
Amyl nitrite causes a non specific relaxation of smooth muscle with the most prominent actions occurring in vascular smooth muscle. This effect on vascular smooth muscle results in coronary vasodilation and decreased systemic vascular resistance and left ventricular preload and afterload. Myocardial ischemia is relieved in patients with angina pectoris, with an abatement of chest pain and possibly other related symptons. Amyl nitrite vapors are absorbed rapidly through the pulmonary alveoli, manifesting therapeutic effects within one minute after inhalation. The drug is metabolized rapidly, probably by hydrolytic denitration; approximately one-third of the inhaled amyl nitrite is excreted in the urine.[1]
References
- ↑ "AMYL NITRITE INHALANT [JAMES ALEXANDER CORPORATION]". Retrieved 30 January 2014.